Fair call Chucky.
I didnt see us taking on a P3 trial (AIPAC) without big pharma (and licensing deal).
Any licensing deal would have funded all other trials through phase 2.
BUT this CR has elevated Immutep from a pure R&D to a serious drug developer with marketing and manufacturing ambitions, which opens up multiple new business development options.
It should be remembered that if successful Immutep would have a monopoly in the Lag-3 space (agonist MHC 2) and therefore there is no competition - the possible third ICI pillar - thats huge and hats off to Marc (and Fred et al) for having the foresight and strength to 'step change' up.
Fair call Chucky.I didnt see us taking on a P3 trial (AIPAC)...
-
- There are more pages in this discussion • 59 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.8¢ |
Change
0.008(2.21%) |
Mkt cap ! $515.6M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 36.0¢ | 33.5¢ | $1.780M | 5.088M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 29 | 159984 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 201611 | 27 |
View Market Depth
| Last trade - 14.56pm 18/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |